144 related articles for article (PubMed ID: 34956670)
1. Effects of Intravitreal Aflibercept on the Systemic Insulin-like Growth Factor-I and Vascular Endothelial Growth Factor-A in Patients with Diabetic Retinopathy and Age-Related Macular Degeneration.
Huber AL; Angermann R; Nowosielski Y; Seifarth C; Kralinger MT; Zehetner C
J Ophthalmol; 2021; 2021():7058505. PubMed ID: 34956670
[TBL] [Abstract][Full Text] [Related]
2. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
3. Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic Retinopathy.
Waltl I; Zehetner C; Seifarth C; Handle F; Kieselbach GF; Angermann R; Kralinger MT
Curr Eye Res; 2018 Mar; 43(3):368-375. PubMed ID: 29172741
[TBL] [Abstract][Full Text] [Related]
4. Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
Yoshimoto M; Takeda N; Yoshimoto T; Matsumoto S
J Med Case Rep; 2021 Jul; 15(1):403. PubMed ID: 34311786
[TBL] [Abstract][Full Text] [Related]
5. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Alagorie AR; Nittala MG; Velaga S; Zhou B; Rusakevich AM; Wykoff CC; Sadda SR
JAMA Ophthalmol; 2020 Aug; 138(8):851-857. PubMed ID: 32584384
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
Brown DM; Wykoff CC; Boyer D; Heier JS; Clark WL; Emanuelli A; Higgins PM; Singer M; Weinreich DM; Yancopoulos GD; Berliner AJ; Chu K; Reed K; Cheng Y; Vitti R
JAMA Ophthalmol; 2021 Sep; 139(9):946-955. PubMed ID: 34351414
[TBL] [Abstract][Full Text] [Related]
7. Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration.
Sawada T; Wang X; Sawada O; Saishin Y; Ohji M
Clin Exp Ophthalmol; 2018 Jan; 46(1):46-53. PubMed ID: 28621038
[TBL] [Abstract][Full Text] [Related]
8. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration.
Yoshida I; Shiba T; Taniguchi H; Takahashi M; Murano T; Hiruta N; Hori Y; Bujo H; Maeno T
Graefes Arch Clin Exp Ophthalmol; 2014 Sep; 252(9):1483-9. PubMed ID: 25030237
[TBL] [Abstract][Full Text] [Related]
10. Recovery of plasma vascular endothelial growth factor concentrations during aflibercept loading phase and after the transition to bimonthly treatment for neovascular age-related macular degeneration.
Roald AB; Aass HC; Moe MC
Br J Ophthalmol; 2015 Dec; 99(12):1610-3. PubMed ID: 25966740
[TBL] [Abstract][Full Text] [Related]
11. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
12. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
13. Systemic counterregulatory response of angiopoietin-2 after aflibercept therapy for nAMD: a potential escape mechanism.
Angermann R; Rauchegger T; Nowosielski Y; Seifarth C; Egger S; Kralinger MT; Kieselbach GF; Zehetner C
Acta Ophthalmol; 2021 Sep; 99(6):e869-e875. PubMed ID: 33326179
[TBL] [Abstract][Full Text] [Related]
14. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
[TBL] [Abstract][Full Text] [Related]
15. Retinal and Choroidal Changes after Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration.
Kim SW; Woo JE; Yoon YS; Lee S; Woo JM; Min JK
Curr Pharm Des; 2019; 25(2):184-189. PubMed ID: 30892159
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
18. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
[TBL] [Abstract][Full Text] [Related]
19. One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1171-1176. PubMed ID: 32452251
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]